Given that both ARNIs and SGLT2 inhibitors are now considered foundational pillars of heart failure therapy, there is growing interest in understanding their comparative efficacy, safety profiles, and long-term outcomes [8]. This evidence concerns the gene SLC5A2 and heart failure.